In pharmacology, in vivo observations connect a candidate compound's administered dose with whole-body effects, allowing researchers to examine pharmacokinetics, pharmacodynamics, toxicity, and physiological responses together. This integrated view can show how a treatment behaves after administration and whether desired effects occur alongside adverse reactions. It therefore supplies evidence that complements cell-based and computational studies.
Pharmacokinetics describes how the body handles a compound through absorption, distribution, metabolism, and excretion. Pharmacodynamics focuses on the compound's effects on biological or physiological processes. Evaluating both provides different but connected information: one addresses the compound's movement through the body, while the other addresses its activity and potential therapeutic responses.
A candidate compound may produce a desired physiological effect while also causing harmful responses. Monitoring toxicity and adverse reactions alongside therapeutic activity helps pharmacologists judge the balance between potential benefit and risk. These observations can identify important safety concerns before the compound progresses to carefully regulated clinical research, where human exposure requires additional justification and oversight.
Animal studies provide in vivo evidence, whereas organoids, tissue models, and computational approaches represent alternative or complementary ways to investigate biological effects. Using these approaches together can broaden the evidence available for a candidate compound without relying on one model alone. Their combined role reflects ongoing efforts to develop alternatives while retaining relevant pharmacological information.
A pharmacological study begins with administration of a candidate compound at defined doses. Researchers then monitor pharmacokinetics, pharmacodynamics, toxicity, and physiological responses, including how the compound is absorbed, distributed, metabolized, and excreted. The resulting observations are interpreted as in vivo evidence of potential therapeutic effects and adverse reactions.
Before clinical research, animal studies can provide evidence about a compound's biological activity, handling by the body, potential therapeutic effects, toxicity, and adverse reactions. This information helps characterize the candidate across several pharmacological dimensions rather than relying on a single outcome. Such evidence complements cell-based and computational findings during preclinical evaluation.
The scientific value of animal research must be weighed against ethical responsibilities and humane care requirements. Researchers therefore need to consider not only what the study may reveal about disease mechanisms or candidate treatments, but also the obligations associated with using living animals. The development of organoids, tissue models, and predictive computational approaches further supports responsible reduction of animal use.